Singapore: Japanese pharmaceutical company, Daiichi Sankyo, has received approval from the Ministry of Health, Labour and Welfare in Japan for Lixiana for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and recurrence prevention of venous thromboembolism (VTE).

Lixiana was approved in Japan in April 2011, for the prevention of VTE after major orthopedic surgery and was launched in July 2011. Daiichi Sankyo has also filed for approval of once-daily edoxaban in both the US and EU for the prevention of stroke in NVAF and for symptomatic VTE in patients with DVT and/or pulmonary embolism.